[ad_1]
The European Medicines Agency indicated on Monday that it will only comment on the modern pharmaceutical company’s vaccine against COVID-19 after further consultations, which will resume during the current week.
“AEM debates [Agência Europeia de Medicamentos] on Moderna’s vaccine against covid-19 will not end tonight. They will continue on Wednesday, ”says a statement from the institution, released on Monday.
The European regulator, announcing today an extraordinary meeting of the Committee for Medicinal Products for Human Use, indicated that it could conclude the discussions regarding the vaccine of the American pharmaceutical company.
The meeting could be the culmination of the evaluation of the vaccine developed by the modern pharmaceutical company, which would allow the European Commission (EC) to authorize a conditional license for the use of the drug in European territory.
The continuation of the discussions will continue on Wednesday so that specialists have more time to analyze the clinical and laboratory data made available to them by the American pharmaceutical company.
If a positive conclusion is reached, Moderna’s vaccine will be the second to receive a “green light” from European Union (EU) researchers, following the approval, on December 21, of the drug developed by the pharmaceutical companies Pfizer and BioNTech, which has been in use in Europe since last week.
The committee has also opened since December 1 of last year two processes for real-time review of vaccines developed by the pharmaceutical company Janssen, a subsidiary of the American Johnson & Johnson and the University of Oxford, and Astrazeneca, although neither of them requested a conditional authorization for the use of the medicine in the EU.
Although AEM insisted on the difficulties in defining a timeline for publicizing scientific conclusions about a drug, given that it largely depends on available data and how quickly the pharmacist responds to the committee’s questions, the agency even now it has taken several weeks. give the green light to a vaccine against covid-19.
[ad_2]
